News for Recce Pharmaceuticals Ltd (RCE.AX)

Recce Pharmaceuticals Ltd plans to raise $5 million through a Placement to a private investor in Australia, and an Entitlement Offer

Recce Pharmaceuticals (ASX: RCE) has released positive patient data analysis from a Phase II clinical trial of its Recce 327 topical gel (R327G) for the

**media[521488]**

Just after the local bourse opened, Trump says the U.S. is seriously considering tariffs on China due to the alleged production and distribution of fentanyl.

Recce Pharmaceuticals Ltd has seen its share price rise more than 1% as it completes dosing of all 30 participants

Recce Pharmaceuticals Ltd has secured approval for a Phase 3 trial on its treatment candidate to treat diabetic foot infections

Recce Pharmaceuticals Ltd (ASX:RCE) has ticked off completion of all patents for…

Recce Pharmaceuticals (ASX: RCE) has received a cash refund of $6,751,176 Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for FY24.

The Reserve Bank Board has kept interest rates on hold at 4.35% in line with consensus expectations. RBA Governor Michelle Bullock says the bank wants to be more convinced.

Recce Pharmaceuticals Ltd has reached an important milestone in testing of its R327G gel to treat bacterial skin infections

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.

The ASX200 has hit a fresh all time high of 3,035 points in buoyant Monday trade with the market up 0.8% heading into 1pm.

The ASX200 closed the week up 0.15%. The IT sector finished on top, gaining 0.85%. Financials followed up, gaining 0.6%. Materials took the hardest hit, falling 0.7%.

Microba wraps up autoimmune disease therapeutic discovery program with Ginkgo Bioworks and Imricor completes second iCMR ablation in Croatia.

The ASX200 is up three quarters of a per cent. The Energy sector spurred early gains, driven by Strike Energy (ASX:STX), which is up more than 6 per cent on its update to net gas pay, (ASX:DYL) joins the ASX200 tomorrow and Hancock Prospecting now holds 7.5% of Vulcan Energy Resources (ASX:VUL).

Pharmaceutical companies can bring new hope to patients by delivering solutions to unmet medical needs. They can go from small market cap plays to market giants – but getting there isn't easy, it’s risky, and it can take a lot of money and patience. Hosted by HotCopper and The Market Online's executive producer Sonia Madigan, this webinar demystifies the clinical trials & approvals process.

Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE ® 327 in Lung Infection Pilot Study

The ASX200 closed around 1.3 of a per cent up following the RBA’s decision to keep high interest rates on hold.

The ASX200 closed the day up more than a per cent (1.08%).All sectors bar one finished in the green. Energy fell 1.5 per cent, but Healthcare lead gains, nearly two per cent (1.97%). Telecommunications followed, up 1.7 per cent.